Smith & Nephew SNATS, Inc.
SNN Healthcare Medical Devices
Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024.
Follow SNN
Alert me
Smith & Nephew SNATS, Inc. (SNN) P/E ratio
As of 5 November 2026, Smith & Nephew SNATS, Inc. (SNN) trades at a P/E ratio of 38.9×. Over the past ten years it has ranged from 18.2× (September 2022) to 47.2× (September 2025); the current reading is higher than 94% of that period. That is above the Medical Devices industry median of 25.6× and above the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 40.0× | 33.48% |
| FY2024 | 30.0× | (8.45%) |
| FY2023 | 32.7× | 2.42% |
| FY2022 | 32.0× | 3.67% |
| FY2021 | 30.8× | (11.84%) |
| FY2020 | 35.0× | 7.59% |
| FY2019 | 32.5× | 6.52% |
| FY2018 | 30.5× | (1.57%) |
| FY2017 | 31.0× | 16.37% |
| FY2016 | 26.6× | (15.76%) |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2023 | 39.3× | 23.02% |
| Dec 2022 | 32.0× | 37.89% |
| Jun 2022 | 23.2× | (24.82%) |
| Dec 2021 | 30.8× | (21.92%) |
| 6 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BRKR Bruker Corporation compare | n/m |
| GKOS Glaukos Corporation compare | n/m |
| TXG 10x Genomics compare | n/m |
| BIO Bio-Rad Laboratories, Inc. compare | 9.7× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 9.9× |
| GMED Globus Medical, Inc. compare | 19.5× |
| PODD Insulet Corporation compare | 25.2× |
| SNN Smith & Nephew SNATS, Inc. | 38.9× |
| PEN Penumbra, Inc. compare | 80.3× |
| Medical Devices industry median | 25.6× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on SNN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement